Cartesian Therapeutics (RNAC) Debt Ratio (2015 - 2023)

Cartesian Therapeutics (RNAC) has 9 years of Debt Ratio data on file, last reported at 0.17 in Q2 2023.

• On a quarterly basis, Debt Ratio rose 24.94% year-over-year to 0.17 in Q2 2023; TTM through Jun 2023 was 0.17, a 24.94% increase from a year earlier, with the FY2022 full-year figure at 0.16, down 1.26% from the prior year.
• Debt Ratio for Q2 2023 stood at 0.17, up from 0.17 in the prior quarter.
• Over the last five years, Debt Ratio for RNAC reached as high as 0.53 in Q3 2019 and fell as low as 0.14 in Q3 2020.
• Historically, Debt Ratio has averaged 0.21 across 5 years, with a median of 0.17 in 2021.
• Across the five-year window, Debt Ratio jumped 58.9% in 2019 and tumbled 74.33% in 2020, its largest moves.
• Year by year, Debt Ratio stood at 0.19 in 2019, then fell by 21.07% to 0.15 in 2020, then rose by 6.98% to 0.16 in 2021, then slipped by 1.26% to 0.16 in 2022, then climbed by 8.77% to 0.17 in 2023.
• Per Business Quant data, the three most recent Debt Ratio figures were 0.17 in Q2 2023, 0.17 in Q1 2023, and 0.16 in Q4 2022.